ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Amvuttra 25 mg solution for injection in pre-filled syringe

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each pre-filled syringe contains vutrisiran sodium equivalent to 25 mg vutrisiran in 0.5 mL solution.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for injection (injection).

Clear, colourless-to-yellow solution (pH of approximately 7; osmolality 210 to 390 mOsm/kg).

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Amvuttra is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

4.2 Posology and method of administration

Therapy should be initiated under the supervision of a physician knowledgeable in the management of amyloidosis. Treatment should be started as early as possible in the disease course to prevent the accumulation of disability.

**Posology**

The recommended dose of Amvuttra is 25 mg administered via subcutaneous injection once every 3 months.

Vitamin A supplementation at approximately, but not exceeding, 2 500 IU to 3 000 IU vitamin A per day is advised for patients treated with Amvuttra (see section 4.4).

The decision to continue treatment in those patients whose disease progresses to stage 3 polyneuropathy should be taken at the discretion of the physician based on the overall benefit and risk assessment.

**Missed dose**

If a dose is missed, Amvuttra should be administered as soon as possible. Dosing should be resumed every 3 months, from the most recently administered dose.

**Special populations**

_Elderly patients_

No dose adjustment is required in patients ≥ 65 years of age (see section 5.2).
**Hepatic impairment**
No dose adjustment is necessary in patients with mild hepatic impairment (total bilirubin ≤ 1 x upper limit of normal (ULN) and aspartate aminotransferase (AST) > 1 x ULN, or total bilirubin > 1.0 to 1.5 x ULN and any AST). Vutrisiran has not been studied in patients with moderate or severe hepatic impairment and should only be used in these patients if the anticipated clinical benefit outweighs the potential risk (see section 5.2).

**Renal impairment**
No dose adjustment is necessary in patients with mild or moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 to < 90 mL/min/1.73 m²). Vutrisiran has not been studied in patients with severe renal impairment or end-stage renal disease and should only be used in these patients if the anticipated clinical benefit outweighs the potential risk (see section 5.2).

**Paediatric population**
The safety and efficacy of Amvuttra in children or adolescents < 18 years of age have not been established. No data are available.

**Method of administration**
Amvuttra is for subcutaneous use only. Amvuttra should be administered by a healthcare professional.

This medicinal product is ready-to-use and for single-use only.

Visually inspect the solution for particulate matter and discolouration. Do not use if discoloured or if particles are present.

Prior to administration, if stored cold, the pre-filled syringe should be allowed to warm by leaving carton at room temperature for about 30 minutes.

- The subcutaneous injection should be administered into one of the following sites: the abdomen, thighs, or upper arms. Amvuttra should not be injected into scar tissue or areas that are reddened, inflamed, or swollen.
- If injecting into the abdomen, the area around the navel should be avoided.

**4.3 Contraindications**
Severe hypersensitivity (e.g., anaphylaxis) to the active substance or to any of the excipients listed in section 6.1.

**4.4 Special warnings and precautions for use**

**Vitamin A deficiency**
By reducing serum transthyretin (TTR) protein, Amvuttra treatment leads to a decrease in serum vitamin A (retinol) levels (see section 5.1). Serum vitamin A levels below the lower limit of normal should be corrected and any ocular symptoms or signs due to vitamin A deficiency should be evaluated prior to initiation of treatment with Amvuttra.

Patients receiving Amvuttra should take oral supplementation of approximately, but not exceeding, 2 500 IU to 3 000 IU vitamin A per day to reduce the potential risk of ocular symptoms due to vitamin A deficiency. Ophthalmological assessment is recommended if patients develop ocular symptoms suggestive of vitamin A deficiency, including reduced night vision or night blindness, persistent dry eyes, eye inflammation, corneal inflammation or ulceration, corneal thickening or corneal perforation.

During the first 60 days of pregnancy, both too high or too low vitamin A levels may be associated with an increased risk of foetal malformation. Therefore, pregnancy should be excluded before
initiating Amvuttra and women of childbearing potential should practise effective contraception (see section 4.6). If a woman intends to become pregnant, Amvuttra and vitamin A supplementation should be discontinued and serum vitamin A levels should be monitored and have returned to normal before conception is attempted. Serum vitamin A levels may remain reduced for more than 12 months after the last dose of Amvuttra.

In the event of an unplanned pregnancy, Amvuttra should be discontinued (see section 4.6). No recommendation can be given whether to continue or discontinue vitamin A supplementation during the first trimester of an unplanned pregnancy. If vitamin A supplementation is continued, the daily dose should not exceed 3 000 IU per day, due to the lack of data supporting higher doses. Thereafter, vitamin A supplementation of 2 500 IU to 3 000 IU per day should be resumed in the second and third trimesters if serum vitamin A levels have not yet returned to normal, because of the increased risk of vitamin A deficiency in the third trimester.

It is not known whether vitamin A supplementation in pregnancy will be sufficient to prevent vitamin A deficiency if the pregnant female continues to receive Amvuttra. However, increasing vitamin A supplementation to above 3 000 IU per day during pregnancy is unlikely to correct plasma retinol levels due to the mechanism of action of Amvuttra and may be harmful to the mother and foetus.

**Sodium content**

This medicinal product contains less than 1 mmol sodium (23 mg) per mL, that is to say essentially ‘sodium-free’.

### 4.5 Interaction with other medicinal products and other forms of interaction

No clinical interaction studies have been performed. Vutrisiran is not expected to cause interactions or to be affected by inhibitors or inducers of cytochrome P450 enzymes, or to modulate the activity of transporters. Therefore, vutrisiran is not expected to have clinically significant interactions with other medicinal products.

### 4.6 Fertility, pregnancy and lactation

**Women of childbearing potential**

Treatment with Amvuttra reduces serum levels of vitamin A. Both too high or too low vitamin A levels may be associated with an increased risk of foetal malformation. Therefore, pregnancy should be excluded before initiation of treatment and women of childbearing potential should use effective contraception. If a woman intends to become pregnant, Amvuttra and vitamin A supplementation should be discontinued and serum vitamin A levels should be monitored and have returned to normal before conception is attempted (see section 4.4.). Serum vitamin A levels may remain reduced for more than 12 months after the last dose of treatment.

**Pregnancy**

There are no data on the use of Amvuttra in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). Due to the potential teratogenic risk arising from unbalanced vitamin A levels, Amvuttra should not be used during pregnancy. As a precautionary measure, vitamin A (see section 4.4) and thyroid stimulating hormone levels should be obtained early in pregnancy. Close monitoring of the foetus should be carried out, especially during the first trimester.

**Breast-feeding**

It is unknown whether vutrisiran is excreted in human milk. There is insufficient information on the excretion of vutrisiran in animal milk (see section 5.3).
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Amvuttra, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

**Fertility**

There are no data on the effects of Amvuttra on human fertility. No impact on male or female fertility was detected in animal studies (see section 5.3).

### 4.7 Effects on ability to drive and use machines

Amvuttra has no or negligible influence on the ability to drive and use machines.

### 4.8 Undesirable effects

**Summary of the safety profile**

During the HELIOS-A 18-month treatment period, the most frequently occurring adverse reactions reported in Amvuttra-treated patients were pain in extremity (15%) and arthralgia (11%).

**Tabulated list of adverse reactions**

The adverse reactions are presented as MedDRA preferred terms and under the MedDRA System Organ Class (SOC). The frequency of the adverse reactions is expressed according to the following categories:

- Very common (≥1/10)
- Common (≥1/100 to <1/10)
- Uncommon (≥1/1 000 to <1/100)

**Table 1: Adverse reactions reported for Amvuttra**

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Adverse reaction</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory, thoracic, and mediastinal disorders</td>
<td>Dyspnoea(^a)</td>
<td>Common</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Arthralgia</td>
<td>Very common</td>
</tr>
<tr>
<td></td>
<td>Pain in extremity</td>
<td>Very common</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Injection site reaction(^b)</td>
<td>Common</td>
</tr>
<tr>
<td>Investigations</td>
<td>Blood alkaline phosphatase increased</td>
<td>Common</td>
</tr>
</tbody>
</table>

\(^a\) Includes dyspnoea, dyspnoea exertional and dyspnoea paroxysmal nocturnal

\(^b\) Reported symptoms included bruising, erythema, pain, pruritus, and warmth. Injection site reactions were mild, transient, and did not lead to treatment discontinuation

**Description of selected adverse reactions**

**Immunogenicity**

During the HELIOS-A 18-month treatment period, 4 (3.3%) Amvuttra-treated patients developed anti-drug antibodies (ADA). ADA titres were low and transient with no evidence of an effect on clinical efficacy, safety, or pharmacokinetic or pharmacodynamic profiles of vutrisiran.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

In case of overdose, it is recommended that the patient be monitored as medically indicated for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other Nervous System Drugs; ATC code: N07XX18

Mechanism of action

Amvuttra contains vutrisiran, a chemically stabilized double-stranded small interfering ribonucleic acid (siRNA) that specifically targets variant and wild-type transthyretin (TTR) messenger RNA (mRNA) and is covalently linked to a ligand containing three N-acetylgalactosamine (GalNAc) residues to enable delivery of the siRNA to hepatocytes.

Through a natural process called RNA interference (RNAi), vutrisiran causes the catalytic degradation of TTR mRNA in the liver, resulting in the reduction of variant and wild-type serum TTR protein levels.

Pharmacodynamic effects

Mean serum TTR was reduced as early as Day 22, with mean near to steady state TTR reduction of 73% by Week 6. With repeat dosing of 25 mg once every 3 months, mean reductions of serum TTR after 9 and 18 months of treatment were 83% and 88%, respectively. Similar TTR reductions were observed regardless of genotype (V30M or non-V30M), prior TTR stabiliser use, weight, sex, age, or race.

Serum TTR is a carrier of retinol binding protein 4, which is the principal carrier of vitamin A in the blood. Amvuttra decreased vitamin A levels with mean steady state peak and trough reductions of 70% and 63%, respectively (see sections 4.4 and 4.5).

Clinical efficacy and safety

The efficacy of Amvuttra was studied in a global, randomised, open-label clinical study (HELIOS-A) in adult patients with hATTR amyloidosis with polyneuropathy. Patients were randomised 3:1 to receive 25 mg of Amvuttra (N=122) subcutaneously once every 3 months, or 0.3 mg/kg patisiran (N=42) intravenously once every 3 weeks. The treatment period of the study was conducted over 18 months with two analyses at Month 9 and at Month 18. Ninety-seven percent (97%) of Amvuttra-treated patients completed at least 18 months of the assigned treatments (vutrisiran or patisiran). Efficacy assessments were based on a comparison of the vutrisiran arm of the study with an external placebo group (placebo arm of the APOLLO Phase 3 study) comprised of a similar population of patients with hATTR amyloidosis with polyneuropathy. Assessment of non-inferiority of serum TTR reduction was based on comparison of the vutrisiran arm to the within-study patisiran arm.

Of the patients who received Amvuttra, the median patient age at baseline was 60 years (range 34 to 80 years), 38% were ≥65 years old, and 65% of patients were male. Twenty-two (22) different TTR variants were represented: V30M (44%), T60A (13%), E89Q (8%), A97S (6%), S50R (4%), V122I (3%), L58H (3%), and Other (18%). Twenty percent (20%) of patients had the V30M genotype and early onset of symptoms (<50 years old). At baseline, 69% of patients had stage 1 disease (unimpaired ambulation; mild sensory, motor, and autonomic neuropathy in the lower limbs), and 31%
had stage 2 disease (assistance with ambulation required; moderate impairment of the lower limbs, upper limbs, and trunk). There were no patients with stage 3 disease. Sixty-one percent (61%) of patients had prior treatment with TTR tetramer stabilisers. According to the New York Heart Association (NYHA) classification of heart failure, 9% of patients had class I and 35% had class II. Thirty-three percent (33%) of patients met pre-defined criteria for cardiac involvement (baseline LV wall thickness ≥ 13 mm with no history of hypertension or aortic valve disease).

The primary efficacy endpoint was the change from baseline to Month 18 in modified Neuropathy Impairment Score +7 (mNIS+7). This endpoint is a composite measure of motor, sensory, and autonomic neuropathy including assessments of motor strength, reflexes, quantitative sensory testing, nerve conduction studies, and postural blood pressure, with the score ranging from 0 to 304 points, where an increasing score indicates worsening impairment.

The change from baseline to Month 18 in Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) total score was assessed as a secondary endpoint. The Norfolk QoL-DN questionnaire (patient-reported) includes domains relating to small fibre, large fibre, and autonomic nerve function, symptoms of polyneuropathy, and activities of daily living, with the total score ranging from -4 to 136, where increasing score indicates worsening quality of life.

Other secondary endpoints included gait speed (10-meter walk test), nutritional status (mBMI), and patient-reported ability to perform activities of daily living and social participation (Rasch-Built Overall Disability Scale [R-ODS]).

Treatment with Amvuttra in the HELIOS-A study demonstrated statistically significant improvements in all endpoints (Table 2 and Figure 1) measured from baseline to Month 9 and 18, compared to the external placebo group of the APOLLO study (all \( p < 0.0001 \)).

The time-averaged trough TTR percent reduction through Month 18 was 84.7% for vutrisiran and 80.6% for patisiran. The percent reduction in serum TTR levels in the vutrisiran arm was non-inferior (according to predefined criteria) to the within-study patisiran arm through Month 18 with a median difference of 5.3% (95% CI 1.2%, 9.3%).
Table 2: Summary of clinical efficacy results from the HELIOS-A study

<table>
<thead>
<tr>
<th>Endpointa</th>
<th>Baseline, Mean (SD)</th>
<th>Change from Baseline, LS Mean (SEM)</th>
<th>Amvuttra -Placebo Treatment Difference, LS Mean (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Amvuttra N=122</td>
<td>Placebo N=77</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Month 9</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mNIS+7c</td>
<td>60.6 (36.0)</td>
<td>74.6 (37.0)</td>
<td>-2.2 (1.4)</td>
<td>-17.0 (-21.8, -12.2)</td>
</tr>
<tr>
<td>Norfolk QoL-DNc</td>
<td>47.1 (26.3)</td>
<td>55.5 (24.3)</td>
<td>-3.3 (1.7)</td>
<td>-16.2 (-21.7, -10.8)</td>
</tr>
<tr>
<td>10-meter walk test (m/sec)d</td>
<td>1.01 (0.39)</td>
<td>0.79 (0.32)</td>
<td>0 (0.02)</td>
<td>0.13 (0.07, 0.19)</td>
</tr>
<tr>
<td><strong>Month 18</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mNIS+7c</td>
<td>60.6 (36.0)</td>
<td>74.6 (37.0)</td>
<td>-0.5 (1.6)</td>
<td>-28.5 (-34.0, -23.1)</td>
</tr>
<tr>
<td>Norfolk QoL-DNc</td>
<td>47.1 (26.3)</td>
<td>55.5 (24.3)</td>
<td>-1.2 (1.8)</td>
<td>-21.0 (-27.1, -14.9)</td>
</tr>
<tr>
<td>10-meter walk test (m/sec)d</td>
<td>1.01 (0.39)</td>
<td>0.79 (0.32)</td>
<td>-0.02 (0.03)</td>
<td>0.24 (0.15, 0.33)</td>
</tr>
<tr>
<td>mBMIe</td>
<td>1057.5 (233.8)</td>
<td>989.9 (214.2)</td>
<td>25.0 (9.5)</td>
<td>140.7 (108.4, 172.9)</td>
</tr>
<tr>
<td>R-ODSf</td>
<td>34.1 (11.0)</td>
<td>29.8 (10.8)</td>
<td>-1.5 (0.6)</td>
<td>8.4 (6.5, 10.4)</td>
</tr>
</tbody>
</table>

Abbreviations: CI=confidence interval; LS mean=least squares mean; mBMI=modified body mass index; mNIS=modified Neuropathy Impairment Score; QoL-DN=Quality of Life - Diabetic Neuropathy; SD=standard deviation; SEM=standard error of the mean

* All Month 9 endpoints analyzed using the analysis of covariance (ANCOVA) with multiple imputation (MI) method and all Month 18 analyzed using the mixed-effects model for repeated measures (MMRM)

* External placebo group from APOLLO randomised controlled study

* A lower number indicates less impairment/fewer symptoms

* A higher number indicates less disability/less impairment

* mBMI: body mass index (BMI; kg/m²) multiplied by serum albumin (g/L); a higher number indicates better nutritional status.

* A higher number indicates less disability/less impairment.
Figure 1: Change from Baseline in mNIS+7 (Month 9 and Month 18)

A decrease in mNIS+7 indicates improvement

\( \Delta \) indicates between-group treatment difference, shown as the LS mean difference (95% CI) for AMVUTTRA – external placebo

All Month 9 endpoints analyzed using the analysis of covariance (ANCOVA) with multiple imputation (MI) method and all Month 18 analyzed using the mixed-effects model for repeated measures (MMRM)

\( ^{a} \) External placebo group from APOLLO randomised controlled study

Patients receiving Amvuttra experienced similar benefit relative to placebo in mNIS+7 and Norfolk QoL-DN total score at Month 9 and Month 18 across all subgroups including age, sex, race, region, NIS score, V30M genotype status, prior TTR stabiliser use, disease stage, and patients with or without pre-defined criteria for cardiac involvement.

The N-terminal prohormone-B-type natriuretic peptide (NT-proBNP) is a prognostic biomarker of cardiac dysfunction. NT-proBNP baseline values (geometric mean) were 273 ng/L and 531 ng/L in Amvuttra-treated and placebo-treated patients, respectively. At Month 18, the geometric mean NT-proBNP levels decreased by 6% in Amvuttra patients, while there was a 96% increase in placebo patients.

Centrally-assessed echocardiograms showed changes in LV wall thickness (LS mean difference: -0.18 mm [95% CI -0.74, 0.38]) and longitudinal strain (LS mean difference: -0.4% [95% CI -1.2, 0.4]) with Amvuttra treatment relative to placebo.

Despite the observed values for NT-proBNP and LV wall thickness, a clinical benefit in regard to cardiomyopathy is yet to be confirmed.

Paediatric population

The European Medicines Agency has waived the obligation to submit the results of studies with vutrisiran in all subsets of the paediatric population in hATTR amyloidosis (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

The pharmacokinetic properties of Amvuttra were characterised by measuring the plasma and urine concentrations of vutrisiran.
Absorption

Following subcutaneous administration, vutrisiran is rapidly absorbed with a time to maximum plasma concentration ($t_{\text{max}}$) of 3.0 (range: 2.0 to 6.5) hours. At the recommended dosing regimen of 25 mg once every 3 months subcutaneously, the mean (% coefficient of variation [%CV]) steady state peak concentrations ($C_{\text{max}}$), and area under the concentration time curve from 0 to 24 hours (AUC$_{0-24}$) were 0.12 µg/mL (64.3%), and 0.80 µg·h/mL (35.0%), respectively. There was no accumulation of vutrisiran in plasma after repeated quarterly dosing.

Distribution

Vutrisiran is greater than 80% bound to plasma proteins over the concentration range observed in humans at the dose of 25 mg once every 3 months subcutaneously. Vutrisiran plasma protein binding was concentration-dependent and decreased with increasing vutrisiran concentrations (from 78% at 0.5 µg/mL to 19% at 50 µg/mL). The population estimate for the apparent central compartment volume of distribution (Vd/F) of vutrisiran in humans was 10.2 L (% Relative standard error [RSE]=5.71%). Vutrisiran distributes primarily to the liver after subcutaneous dosing.

Biotransformation

Vutrisiran is metabolised by endo- and exo-nucleases to short nucleotide fragments of varying sizes within the liver. There were no major circulating metabolites in humans. *In vitro* studies indicate that vutrisiran does not undergo metabolism by CYP450 enzymes.

Elimination

Following a 25 mg single subcutaneous dose, the median apparent plasma clearance was 21.4 (range: 19.8, 30.0) L/h. The median terminal elimination half-life ($t_{1/2}$) of vutrisiran was 5.23 (range: 2.24, 6.36) hours. After a single subcutaneous dose of 5 to 300 mg, the mean fraction of unchanged active substance eliminated in urine ranged from 15.4 to 25.4% and the mean renal clearance ranged from 4.45 to 5.74 L/h for vutrisiran.

Linearity/non-linearity

Following single subcutaneous doses over the 5 to 300 mg dose range, vutrisiran $C_{\text{max}}$ was shown to be dose proportional while area under the concentration-time curve from the time of dosing extrapolated to infinity (AUC$_{\text{lax}}$) and area under the concentration-time curve from the time of dosing to the last measurable concentration (AUC$_{\text{last}}$) were slightly more than dose proportional.

Pharmacokinetic/pharmacodynamic relationship(s)

Population pharmacokinetic/pharmacodynamic analyses in healthy subjects and patients with hATTR amyloidosis (n=202) showed a dose-dependent relationship between predicted vutrisiran liver concentrations and reductions in serum TTR. The model-predicted median steady state peak, trough, and average TTR reductions were 88%, 86%, and 87%, respectively, confirming minimal peak-to-trough variability across the 3-month dosing interval. Covariate analysis indicated similar TTR reduction in patients with mild-to-moderate renal impairment or mild hepatic impairment, as well as by sex, race, prior use of TTR stabilisers, genotype (V30M or non-V30M), age and weight.

Special populations

*Gender and race*

Clinical studies did not identify significant differences in steady state pharmacokinetic parameters or TTR reduction according to gender or race.
Elderly patients
In the HELIOS-A study, 46 (38%) patients treated with vutrisiran were ≥ 65 years old and of these 7 (5.7%) patients were ≥ 75 years old. There were no significant differences in steady state pharmacokinetic parameters or TTR reduction between patients < 65 years old and ≥ 65 years old.

Hepatic impairment
Population pharmacokinetic and pharmacodynamic analyses indicated no impact of mild hepatic impairment (total bilirubin ≤ 1 x ULN and AST > 1 x ULN, or total bilirubin > 1.0 to 1.5 x ULN and any AST) on vutrisiran exposure or TTR reduction compared to patients with normal hepatic function. Vutrisiran has not been studied in patients with moderate or severe hepatic impairment.

Renal impairment
Population pharmacokinetic and pharmacodynamic analyses indicated no impact of mild or moderate renal impairment (eGFR ≥ 30 to < 90 mL/min/1.73 m²) on vutrisiran exposure or TTR reduction compared to subjects with normal renal function. Vutrisiran has not been studied in patients with severe renal impairment or end-stage renal disease.

5.3 Preclinical safety data

General toxicology
Repeated once-monthly subcutaneous administration of vutrisiran at ≥ 30 mg/kg in monkeys produced the expected sustained reductions of circulating TTR (up to 99%) and vitamin A (up to 89%) without any apparent toxicological findings.

Following once monthly repeated dosing for up to 6 months in rats and 9 months in monkeys, the mild and consistent non-adverse histological changes in liver (hepatocytes, Kupffer cells), kidneys (renal tubules), lymph nodes and injection sites (macrophages) reflected the principal distribution and accumulation of vutrisiran. However, no toxicities were identified at up to more than 1 000- and 3 000-fold higher plasma AUC, when normalised to quarterly dosing and compared to the anticipated exposure at the maximum recommended human dose [MRHD].

Genotoxicity/Carcinogenicity
Vutrisiran did not exert any genotoxic potential in vitro and in vivo. Carcinogenicity studies have not been completed.

Reproductive toxicity
Vutrisiran is not pharmacologically active in rats and rabbits, which limits the predictivity of these investigations. Nevertheless, a single dose of a rat-specific orthologue of vutrisiran did not impact on fertility and early embryonic development in a combined study in rats.

Weekly subcutaneous administrations of vutrisiran did not affect fertility and early embryonic development at more than 300-times the normalised MRHD In an embryo-foetal study with daily subcutaneous vutrisiran administration in pregnant rats, adverse effects on maternal body weight, food consumption, increased premature delivery and post-implantation loss were observed with a maternal NOAEL of 10 mg/kg/day that was more than 300-times the normalised MRHD of 0.005 mg/kg/day. Based on an adverse reduction in foetal body weights and increased skeletal variations at ≥10 mg/kg/day, the foetal NOAEL of vutrisiran was 3 mg/kg/day which is 97-times the normalised MRHD.

In an embryo-foetal development study in pregnant rabbits, no adverse effects on embryo-foetal development were observed at ≤ 30 mg/kg/day vutrisiran, which is more than 1900-times the normalised MRHD.
In a prenatal-postnatal development study, subcutaneous vutrisiran administration on every 6th day had no effect on growth and development of the offspring with a NOAEL of 20 mg/kg, which was more than 90-times the normalised MRHD.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium dihydrogen phosphate dihydrate
Disodium phosphate dihydrate
Sodium chloride
Water for injections
Sodium hydroxide (for pH adjustment)
Phosphoric acid (for pH adjustment).

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

Do not store above 30 °C. Do not freeze.

6.5 Nature and contents of container

Pre-filled syringe (Type I glass) with stainless steel 29-gauge needle with a needle shield.

Amvuttra is available in packs containing one single-use pre-filled syringe.

6.6 Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Alnylam Netherlands B.V.
Antonio Vivaldistraat 150
1083 HP Amsterdam
Netherlands

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/22/1681/001

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORIZAION

Date of first authorisation: 15 September 2022
10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Alnylam Netherlands B.V.
Antonio Vivaldistraat 150
1083 HP Amsterdam
Netherlands

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this medicinal product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

**OUTER CARTON**

---

#### 1. NAME OF THE MEDICINAL PRODUCT

Amvuttra 25 mg solution for injection in pre-filled syringe
vutrisiran

#### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe contains vutrisiran sodium equivalent to 25 mg vutrisiran in 0.5 mL solution

#### 3. LIST OF EXCIPIENTS

Sodium dihydrogen phosphate dihydrate, disodium phosphate dihydrate, sodium chloride, sodium hydroxide, phosphoric acid, water for injections

See package leaflet for further information

#### 4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection
1 pre-filled syringe

#### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use
Subcutaneous use
For single use only

#### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children

#### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

---

#### 8. EXPIRY DATE

EXP

#### 9. SPECIAL STORAGE CONDITIONS

Do not store above 30 °C
Do not freeze
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Alnylam Netherlands B.V.
Antonio Vivaldistraat 150
1083 HP Amsterdam
Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/22/1681/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Amvuttra

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRE-FILLED SYRINGE TRAY LID</td>
</tr>
</tbody>
</table>

| 1.  NAME OF THE MEDICINAL PRODUCT               |
| Amvuttra 25 mg solution for injection in pre-filled syringe  
  vutrisiran                                      |

| 2.  NAME OF THE MARKETING AUTHORISATION HOLDER |
| Alnylam Netherlands B.V.                        |

| 3.  EXPIRY DATE                                 |
| EXP                                             |

| 4.  BATCH NUMBER                                |
| Lot                                            |

<p>| 5.  OTHER                                      |
| Subcutaneous use                               |
| For single use only                           |</p>
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRE-FILLED SYRINGE LABEL</td>
</tr>
</tbody>
</table>

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Amvuttra 25 mg injection
vutrisiran
SC

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

25 mg/0.5 mL

6. OTHER
B. PACKAGE LEAFLET
Package leaflet: Information for the patient

Amvuttra 25 mg solution for injection in pre-filled syringe
vutrisiran

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist, or nurse.
- If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Amvuttra is and what it is used for
2. What you need to know before you are given Amvuttra
3. How Amvuttra is given
4. Possible side effects
5. How to store Amvuttra
6. Contents of the pack and other information

1. What Amvuttra is and what it is used for

The active substance in Amvuttra is vutrisiran.

What Amvuttra is used for

Amvuttra is used for the treatment of an illness called ‘hereditary ATTR’ or ‘hATTR amyloidosis’. This is an illness which runs in families. hATTR amyloidosis is caused by problems with a protein in the body called ‘transthyretin’ (TTR). This protein is made mostly in the liver and carries vitamin A and other substances around the body.

In people with this illness, small fibres of TTR protein clump together to make deposits called ‘amyloid’. Amyloid can build up around or within the nerves, heart, and other places in the body, stopping them from working normally. This causes the symptoms of the illness.

How Amvuttra works

Amvuttra works by lowering the amount of TTR protein made by the liver which means there is less TTR protein in the blood that can form amyloid. This can help to reduce the effects of this illness.

Amvuttra is used in adults only.

2. What you need to know before you are given Amvuttra

You must not be given Amvuttra

- If you have ever had a severe allergic reaction to vutrisiran, or any of the other ingredients of this medicine (listed in section 6).
If you are not sure, talk to your doctor, pharmacist or nurse before you are given this medicine.

**Warnings and precautions**

**Lowered vitamin A levels in the blood and vitamin supplements**

Amvuttra lowers the amount of vitamin A in your blood. Your doctor will ask you to take a daily vitamin A supplement. Please follow the vitamin A dose recommended by your doctor.

Signs of low vitamin A may include: sight problems especially at night, dry eyes, hazy, or cloudy vision.
- If you notice a change in your vision or any other eye problems whilst using Amvuttra, talk to your doctor. Your doctor may send you to an eye specialist for a check-up.

Both too high and too low levels of vitamin A can harm the development of your unborn child. Therefore, women of childbearing age should exclude any pregnancy before starting treatment with Amvuttra and practise effective contraception (see section “Pregnancy, breast-feeding and contraception” below).
- Vitamin A levels may remain low for more than 12 months after the last dose of Amvuttra.
- Tell your doctor if you are planning to become pregnant. Your doctor will tell you to stop taking Amvuttra and vitamin A supplementation. Your doctor will also ensure that your vitamin A levels have returned to normal before conception is attempted.
- Tell your doctor if you have an unplanned pregnancy. Your doctor will tell you to stop taking Amvuttra. In the first 3 months of your pregnancy, your doctor may tell you to stop taking vitamin A supplementation. During the last 6 months of your pregnancy, you doctor may tell you to resume the vitamin A supplementation if your vitamin A levels have not yet returned to normal, because of the increased risk of vitamin A deficiency during the last 3 months of your pregnancy.

**Children and adolescents**

Amvuttra is not recommended in children and adolescents under 18 years of age.

**Other medicines and Amvuttra**

Tell your doctor, pharmacist, or nurse if you are using, have recently used or might use any other medicines.

**Pregnancy, breast-feeding and contraception**

If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before starting this medicine.

**Pregnancy**

You should not use Amvuttra if you are pregnant.

**Women of childbearing age**

Amvuttra will reduce the level of vitamin A in your blood and vitamin A is important for normal development of your unborn child (see “Warnings and precautions” above).
- You should use effective contraception during treatment with Amvuttra - if you are a woman who is able to become pregnant.
- Talk to your doctor or nurse about suitable methods of contraception.
- Pregnancy should be excluded before starting treatment with Amvuttra.
- Tell your doctor if you are planning to become pregnant or if you have an unplanned pregnancy. Your doctor will tell you to stop taking Amvuttra.
Breast-feeding

It is not known if vutrisiran passes into breast milk. Your doctor will consider the potential benefits of treatment for you - compared with the risks of breast-feeding for your baby.

Driving and using machines

Amvuttra is unlikely to affect your ability to drive or use machines. Your doctor will tell you whether your condition allows you to drive vehicles and use machines safely.

Amvuttra contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per mL, that is to say essentially ‘sodium-free’.

3. How Amvuttra is given

This medicine will be given to you by a doctor, pharmacist, or nurse.

How much Amvuttra you are given

The recommended dose is 25 mg once every 3 months.

Where the injection is given

Amvuttra is given by injection under the skin (‘subcutaneous injection’) into your stomach area (abdomen), upper arm or thigh.

How long to use Amvuttra

Your doctor will tell you how long you need to receive Amvuttra. Do not stop treatment with Amvuttra unless your doctor tells you to.

If you receive more Amvuttra than you should

In the unlikely event that you are given too much (an overdose), your doctor will check you for side effects.

If you miss your dose of Amvuttra

If you miss an appointment for your Amvuttra injection, contact your doctor, pharmacist or nurse as soon as you can to arrange to have the injection you missed.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor, pharmacist, or nurse if you notice any of the following side effects:

**Very common:** may affect more than 1 in 10 people
- Pain in the joints
- Pain in arms and legs
Common: may affect up to 1 in 10 people
- Being short of breath
- Redness, pain, itching, bruising, or warmth where the injection was given
- Blood tests showing increases in a liver enzyme called alkaline phosphatase

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Amvuttra

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label, tray lid and carton after ‘EXP’. The expiry date refers to the last day of that month.

Do not store above 30 °C. Do not freeze.

Medicines should not be disposed of via wastewater or household waste. Your healthcare professional will throw away any medicines that are no longer being used. These measures will help protect the environment.

6. Contents of the pack and other information

What Amvuttra contains

- The active substance is vutrisiran.
  Each pre-filled syringe contains vutrisiran sodium equivalent to 25 mg vutrisiran in 0.5 mL solution.
- The other ingredients are: sodium dihydrogen phosphate dihydrate, disodium phosphate dihydrate, sodium chloride and water for injections. Sodium hydroxide and phosphoric acid may be used to adjust the pH (see “Amvuttra contains sodium” in section 2).

What Amvuttra looks like and contents of the pack

This medicine is a clear, colourless-to-yellow solution for injection (injection). Each pack contains one single-use pre-filled syringe.

Marketing Authorisation Holder and Manufacturer

Alnylam Netherlands B.V.
Antonio Vivaldistraat 150
1083 HP Amsterdam
Netherlands

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
België/Belgique/Belgien
Alnylam Netherlands B.V.
Tél/Tel: 0800 81 443 (+32 234 208 71)
medinfo@alnylam.com

България
Genesis Pharma Bulgaria EOOD
Тел.: +359 2 969 3227
medinfo@genesispharmagroup.com

Česká republika
Alnylam Czech s.r.o.
Tel: 800 050 450 (+420 234 092 195)
medinfo@alnylam.com

Danmark
Alnylam Sweden AB
Tlf: 433 105 15 (+45 787 453 01)
medinfo@alnylam.com

Deutschland
Alnylam Germany GmbH
Tel: 08002569526 (+49 8920190112)
medinfo@alnylam.com

Ελλάδα
ΓΕΝΕΣΙΣ ΦΑΡΜΑ Α.Ε
Τηλ: +30 210 87 71 500
medinfo@genesispharmagroup.com

España
Alnylam Pharmaceuticals Spain SL
Tel: 900810212 (+34 910603753)
medinfo@alnylam.com

France
Alnylam France SAS
Tél: 0805542656 (+33 187650921)
medinfo@alnylam.com

Hrvatska
Genesis Pharma Adriatic d.o.o
Tel: +385 1 5813 652
medinfo@genesispharmagroup.com

Ireland
Alnylam Netherlands B.V.
Tel: 1800 924260 (+353 818 882213)
medinfo@alnylam.com

Italia
Alnylam Italy S.r.l.
Tel: 800 90 25 37 (+39 02 89 73 22 91)
medinfo@alnylam.com

Luxembourg/Luxemburg
Alnylam Netherlands B.V.
Tél/Tel: 80085235 (+352 203 014 48)
medinfo@alnylam.com

Malta
Genesis Pharma (Cyprus) Ltd
Tel: +357 22765715
medinfo@genesispharmagroup.com

Nederland
Alnylam Netherlands B.V.
Tel: 08002820025 (+31 203697861)
medinfo@alnylam.com

Norge
Alnylam Sweden AB
Tlf: 800 544 00 (+47 1405 657)
medinfo@alnylam.com

Österreich
Alnylam Austria GmbH
Tel: 0800070339 (+43 720 778 072)
medinfo@alnylam.com

Portugal
Alnylam Portugal
Tel: 707201512 (+351 707502642)
medinfo@alnylam.com

România
Genesis Biopharma Romania SRL
Tel: +40 21 403 4074
medinfo@genesispharmagroup.com

Slovenija
Genesis Pharma Adriatic d.o.o
Tel: +385 1 5813 652
medinfo@genesispharmagroup.com

Suomi/Finland
Alnylam Sweden AB
Puh/Tel: 0800 417 452 (+358 942 727 020)
medinfo@alnylam.com

Sverige
Alnylam Sweden AB
Tel: 020109162 (+46 842002641)
medinfo@alnylam.com

United Kingdom (Northern Ireland)
Alnylam UK Ltd.
Tel: 08001412569 (+44 1628 878592)
medinfo@alnylam.com
This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:

------------------------------------------------------------------------------------------------------------------------
The following information is intended for healthcare professionals only:

**Amvuttra 25 mg solution for injection in pre-filled syringe**

**vutrisiran**

Healthcare professionals should refer to the Summary of Product Characteristics for full prescribing information.

**Posology and method of administration**

Therapy should be initiated under the supervision of a physician knowledgeable in the management of amyloidosis.

**Posology**
The recommended dose is 25 mg vutrisiran administered by subcutaneous injection once every 3 months.

**Missed dose**
If a dose is missed, administer Amvuttra as soon as possible. Resume dosing every 3 months, from the most recently administered dose.

**Method of administration**
Amvuttra is for subcutaneous use only and should be administered by a healthcare professional.

Prior to administration, if stored cold, allow Amvuttra to warm by leaving carton at room temperature for about 30 minutes.
- Administer subcutaneous injection into one of the following sites: the abdomen, thighs, or upper arms. Do not inject into scar tissue or areas that are reddened, inflamed, or swollen.
- If injecting into the abdomen, avoid the area around the navel.
- Each 25 mg dose is administered using a single pre-filled syringe. Each pre-filled syringe is for single-use only.

**How the syringe looks before and after use:**

**Before Use**

- Needle cap
- Needle
- Syringe body
- Drug solution
- Syringe label
- Finger flange
- Thumb pad
- Plunger rod

**After Use**

- Needle shield (Locked)
1. **Prepare syringe**

   If stored cold, allow the syringe to warm to room temperature for 30 minutes prior to use.

   Remove the syringe from the packaging by gripping the syringe body.

   **Do not** touch plunger rod until ready to inject.

   Amvuttra is a sterile, preservative-free, clear, colourless-to-yellow solution. Visually inspect the solution. **Do not** use if it contains particulate matter or if it is cloudy or discoloured.

   Check:
   - Syringe is not damaged, such as cracked or leaking
   - Needle cap is attached to the syringe
   - Expiry date on syringe label.

   **Do not** use the syringe if any issues are found while checking the syringe.

2. **Choose injection site**

   Choose an injection site from the following areas: the abdomen, thighs, or upper arms.

   Avoid:
   - Area around the navel
   - Scar tissue or areas that are reddened, inflamed, or swollen.

   Clean the chosen injection site.

3. **Prepare for injection**

   Hold the syringe body with one hand. Pull the needle cap straight off with other hand and dispose of needle cap immediately. It is normal to see a drop of liquid at the tip of the needle.

   **Do not** touch the needle or let it touch any surface.

   **Do not** recap the syringe.

   **Do not** use the syringe if it is dropped.

4. **Perform Injection**

   Pinch the cleaned skin.

   Fully insert the needle into the pinched skin at a 45-90° angle.
Inject all of the medicine

**Push the plunger rod as far as it will go** to administer the dose and activate the needle shield.

Release the plunger rod to allow the needle shield to cover the needle.

**Do not** block plunger rod movement.

5. Dispose of syringe

**Immediately dispose** of the used syringe into a sharps container.